PDS Biotechnology Corporation (PDSB) Cash Flow Statement
Where PDSB’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$27.8M
- Capital expenditures
- $0
- Free cash flow
- −$27.8M
- Returned to shareholders
- —
- Change in cash
- −$15.0M cash at year-end $26.7M
Cash from operations
−$27.8M
Net borrowing (repayment)
−$7.6M
Shares issued
+$14.0M
Other financing
+$6.4M
Change in cash
−$15.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
PDSB operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
PDSB cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$32.2M2016 | −$27.8M2025 | — | |
| Capital expenditures | $687,0002016 | $02025 | −100.0% | |
| Free cash flow | −$32.9M2016 | −$27.8M2025 | — | |
| Stock-based compensation | $5.3M2016 | $4.1M2025 | −2.8%/yr | |
| Share buybacks (net) | $02016 | $2712022 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PDSB cash flow by activity
OperatingInvestingFinancingChange in cash
PDSB net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
PDSB cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$34.5M | −$37.6M | −$42.9M | −$40.9M | −$16.9M | −$14.8M | −$7.0M | −$40.9M | −$50.9M | −$38.8M |
| Depreciation & amortization | $21,836 | $21.1M | $57,326 | $86 | $5,357 | $15,608 | $98,414 | $69,118 | $182,918 | $100,117 |
| Stock-based compensation | $4.1M | $6.8M | $7.6M | $5.2M | $4.1M | $452,288 | $3.2M | $7.6M | $6.4M | $5.3M |
| Change in working capital | −$382,971 | −$5.8M | −$199,276 | $4.5M | $75,818 | $1.1M | −$4.6M | −$3.4M | $3.1M | $782,432 |
| Other non-cash items | $3.0M | −$19.6M | $1.8M | $5.5M | $241,031 | $160,684 | −$9.7M | $3.5M | $506,082 | $444,451 |
| Cash from operating activities | −$27.8M | −$35.0M | −$33.6M | −$25.7M | −$12.5M | −$13.1M | −$18.1M | −$33.2M | −$40.7M | −$32.2M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$29,000 | −$4 | −$4 | −$4 | −$5 | −$1 | −$3 | −$189,000 | −$687,000 |
| Investments (net) | — | −$29,000 | $0 | — | — | $275,001 | $29.4M | $0 | −$188,721 | −$686,705 |
| Acquisitions & other investing | — | $29,000 | — | — | — | — | $488 | $29.4M | $188,721 | $686,705 |
| Cash from investing activities | — | −$29,000 | — | — | — | — | $29.4M | $29.4M | −$189,000 | −$687,000 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | −$271 | — | — | — | — | — | — |
| Share repurchases & issuance (net) | — | — | — | −$271 | — | $29.8M | $750,000 | $721,200 | $17.6M | $314,960 |
| Net borrowing (repayment) | −$7.6M | −$3.2M | −$59,300 | $24.6M | $25.0M | $25.0M | $25.0M | −$15,563 | $16,739 | $1.4M |
| Shares issued | $14.0M | $22.6M | $16.1M | $9.9M | $48.5M | $29.8M | $750,000 | $0 | $0 | $0 |
| Other financing | $6.4M | $774,091 | $308,942 | −$119,001 | −$24.7M | −$54.8M | −$25.8M | −$21.0M | $5.0M | $7.4M |
| Cash from financing activities | $12.8M | $20.2M | $16.4M | $34.3M | $48.9M | $29.8M | $750,000 | −$20.3M | $22.6M | $9.1M |
| Summary | ||||||||||
| Net change in cash | −$15.0M | −$14.9M | −$17.3M | $8.6M | $36.4M | $16.7M | $12.1M | −$53.4M | −$18.3M | −$23.8M |
| Cash at end of period | $26.7M | $41.7M | $56.6M | $73.8M | $65.2M | $28.8M | $12.2M | $34.6M | $88.1M | $106.4M |
| Free cash flow | −$27.8M | −$35.1M | −$33.6M | −$25.7M | −$12.5M | −$13.1M | −$18.1M | −$33.2M | −$40.9M | −$32.9M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$9.8M | −$7.3M | −$7.6M | −$9.0M | −$9.4M | −$8.5M | −$8.0M | −$10.7M | −$8.3M | −$10.6M | −$10.9M | −$10.8M |
| Depreciation & amortization | $15,129 | $15,129 | $5,459 | $5,459 | $15,129 | $5,459 | $15,127 | $5,460 | $5,459 | $4,735 | $14,405 | $4,733 |
| Stock-based compensation | $2.28B | $1.2M | $1.2M | $1.2M | $448,029 | $1.3M | $1.6M | $1.8M | $1.8M | $1.6M | $1.4M | $2.1M |
| Change in working capital | $2.9M | $1.4M | $1.8M | $1.4M | −$1.2M | −$2.3M | −$2.2M | $628,443 | −$143,294 | −$1.2M | $400,692 | $1.4M |
| Other non-cash items | −$2.28B | $448,837 | $933,246 | $455,329 | $1.1M | $485,749 | $297,770 | $314,796 | −$2.2M | $279,906 | $671,086 | $208,238 |
| Cash from operating activities | −$2.8M | −$4.4M | −$3.7M | −$5.9M | −$9.1M | −$9.0M | −$8.2M | −$8.0M | −$8.9M | −$9.9M | −$8.5M | −$7.2M |
| Investing activities | ||||||||||||
| Capital expenditures | −$4 | −$4 | −$5 | $0 | −$3 | $0 | −$1 | −$1 | −$28,999 | −$1 | −$4 | $0 |
| Investments (net) | — | — | — | $0 | — | — | $0 | −$1 | — | — | — | $0 |
| Acquisitions & other investing | — | — | — | — | — | — | −$29.0M | $1 | $0 | — | — | — |
| Cash from investing activities | — | — | — | — | — | — | −$29.0M | −$1 | −$28,999 | — | — | — |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | −$14.4M | −$1.5M | −$2.9M | −$1.0M | −$464,721 | −$3.1M | −$3.1M | −$14,105 | — | — | — | — |
| Shares issued | $97,231 | $833,371 | $4.0M | $1.3M | $1.5M | $7.3M | $3.2M | $0 | $0 | $19.5M | $10.5M | $815,202 |
| Other financing | $1.1M | $0 | $3.2M | $0 | $23 | $3.2M | $144,500 | $31,321 | −$13,786 | $517,616 | $286,922 | −$12,876 |
| Cash from financing activities | −$13.3M | −$679,827 | $4.2M | $241,205 | $995,944 | $7.3M | $172,778 | $17,216 | −$13,786 | $20.0M | $10.8M | $802,326 |
| Summary | ||||||||||||
| Net change in cash | −$16.1M | −$5.1M | $513,317 | −$5.7M | −$8.1M | −$1.7M | −$8.1M | −$8.0M | −$8.9M | $10.1M | $2.3M | −$6.4M |
| Cash at end of period | $5.6M | $21.7M | $26.7M | $26.2M | $31.9M | $40.0M | $41.7M | $49.8M | $57.7M | $66.6M | $56.6M | $54.3M |
| Free cash flow | −$2.8M | −$4.4M | −$3.7M | −$5.9M | −$9.1M | −$9.0M | −$8.2M | −$8.0M | −$8.9M | −$9.9M | −$8.5M | −$7.2M |
| Free cash flow margin | — | — | — | — | — | — | −13,941.1% | — | — | — | — | — |
| Capex / revenue | — | — | — | — | — | — | 0.0% | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
PDSB cash generation
In fiscal 2025 (ended December 31, 2025), PDS Biotechnology generated -$27.8 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$27.8 million. Cash and equivalents fell by $15.0 million over the year.
Related: PDSB income statement, PDSB balance sheet. See the PDSB stock overview for the latest quote and news.
PDSB cash flow FAQ
What is PDS Biotechnology's free cash flow?
PDS Biotechnology's free cash flow was -$27.8 million in fiscal 2025: -$27.8 million of operating cash flow minus $0 of capital expenditures It was -$35.1 million a year earlier..
How much cash does PDS Biotechnology generate from operations?
PDS Biotechnology generated -$27.8 million of cash from operating activities in fiscal 2025.